Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Johnson & Johnson’s multiple myeloma drug reduces risk of death in late-stage study

Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.

Read More »

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.

Read More »

Survey Indicates Healthcare Professionals Have a Dim View of Post-Brexit Britain

A new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.

Read More »

Merck Raised Prices Of Five Drugs In November 2018, Including Keytruda

Merck & Co. Inc. raised U.S. prices on five of the company’s drugs in November 2018 by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

Read More »

New Jersey Sues Janssen Over Two Opioid Drugs

State officials from New Jersey took aim at Johnson & Johnson subsidiary Janssen by filing a lawsuit pertaining to the marketing of opioids.

Read More »

WHO uncovers big national variations in antibiotics consumption

Antibiotics are used far more in some countries than in others, a survey by the World Health Organization showed, suggesting that urgent action was needed to slash unnecessary consumption of the medicines.

Read More »

New drug options, risk factors added to U.S. heart guidelines

Updated U.S. guidelines on heart health advise more personalized assessment of risk as well as two newer types of cholesterol-lowering drugs for people at particularly high risk of heart attack or stroke.

Read More »

Novartis division Sandoz recalls one lot of blood pressure drug

Novartis’ Sandoz division recalled one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug.

Read More »

Coherus prices biosimilar to Amgen’s Neulasta at 33 percent discount

Coherus BioSciences Inc. will price the company’s biosimilar to Amgen Inc.’s infection-fighting treatment Neulasta at a 33 percent discount.

Read More »

Amgen cuts price of cholesterol drug Repatha

Amgen Inc., looking to boost use of the U.S. biotechnology company’s potent cholesterol drug Repatha, cut the medication’s U.S. list price by 60 percent to $5,850.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom